Jiangnan University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Wuxi China (1902)

Organization Overview

First Clinical Trial
2012
NCT01591135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Affiliated Hospital of Jiangnan University | Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital) | Jiangnan University

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Dwarfism (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 3)

Gonadal Dysgenesis (Phase 2)

Multiple Myeloma (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 3)

Prostatic Neoplasms (Phase 1)

Syndrome (Phase 2)

Turner Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial APIs: 36